{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.0","value":"3592"},{"groupId":"OG001","spread":"25.0","value":"6755"},{"groupId":"OG002","spread":"21.1","value":"3276"},{"groupId":"OG003","spread":"35.24","value":"3271"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"38"}],"units":"Participants"}],"description":"Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear up/log down rule.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Group A: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG000","title":"AZD4205 Group A"},{"description":"Group B: Open label AZD4205 at 250 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG001","title":"AZD4205 Group B"},{"description":"Group C: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG002","title":"AZD4205 Group C"},{"description":"Group D: Open label AZD4205 at the RP2D, once daily (Phase 2)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG003","title":"AZD4205 Group D"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK population with Intensive PK sampling on Cycle 1, Day 1","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 1 (each cycle = 21 days): 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 hours postdose (for Group A, B and C); 0 (predose), 1, 2, 4, 6, 8, and 24 hours postdose (for Group D).","title":"Part A and Part B: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of AZD4205","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}